

Form Approved OMB No. 0920-0666 Exp. Date: www.cdc.gov/nhsn

Complete this survey as described in the <u>Dialysis Event Protocol</u>.

Instructions: This survey is only for dialysis centers that provide in-center hemodialysis. If your center offers only home dialysis, please complete the Home Dialysis Center Practices Survey. Complete one survey per center. Surveys are completed for the current year. It is strongly recommended that the survey is completed in February of each year by someone who works in the center and is familiar with current practices within the center. Complete the survey based on the actual practices at the center, not necessarily the center policy, if there are differences. Please submit your responses to the questions in this survey electronically by logging into your NHSN facility.

	Please submit your responses to the questions in this survey electronically by logging into your NHSN facility.					
*required	I to save as complete					
Facility	ID #		*Curvoy Voor:			
Facility	Network #:		*Survey Year:			
	ysis Center Information					
A.1. G	eneral					
*1.	What is the ownership of you	r dialysis center? (choose one)				
	☐ Government	☐ Not for profit	☐ For profit			
*2.	a. What is the location/hospit	al affiliation of your dialysis center?	(choose one)			
	☐ Freestanding	☐ Hospital based	☐ Freestanding but	owne	d by a hospit	al
	b. If hospital-based or hospital	al-owned, is your center affiliated w	ith a teaching hospital	l?	□ Yes □	No
*3.	Is your facility accredited by a a. If yes, specify (choose	an organization other than CMS? se one- drop down)			□ Yes □	No
	☐ Joint Commission	☐ National Dialysis Accreditation Committee	☐ Other (specify)			
*4.	a. What types of dialysis serv	vices does your center offer? (selec	t all that apply)			
	☐ In-center daytime hemodialysis	☐ In-center nocturnal hemodialysis	☐ Peritoneal dialysis	□Но	ome hemodia	lysis
	b. What patient population do	oes your center serve? (select one)				
	☐ Adult only	☐ Pediatric only	☐ Mixed: adult and p	pediat	tric	
*5.	How many in-center hemodia	alysis stations does your center hav	re?			
*6.	Is your center part of a group	or chain of dialysis centers?			☐ Yes	□ No
	a. If yes, what is the na	me of the group or chain?				!
*7.	Do you (the person primarily responsible for collecting data for this survey) perform patient				□ No	
*8.	Is there someone at your dia	lysis center in charge of infection co	ontrol?		☐ Yes	□ No
	•	scribes this person? (if >1 person ir	•		ly)	•
	☐ Hospital-affiliated or other infection control practitioner comes to our unit					
	Y	or nurse manager				
		r administrator or director				
	☐ Dialysis educa	<u> </u>				
	☐ Patient care te					
	☐ Other, specify:					



Forr	n App	rove
OMB No.	0920	-066
	Exp.	Date
	1	. / !

2	ational Healthcare						www.cdc	.gov/nhsn
*9.	Does your center provide d dialysis in nursing homes, s					sted	□ Yes	□ No
	a If you have man	v facilities?						
	a. If yes, how mar	iy iaciiilles?						
*10.	Is there a dedicated vascula	ar access nurse/coordinato	or (eithe	er full or part-tim	ne) at vour ce	nter?	☐ Yes	□ No
Assurance collected	Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).							
sources, g required to aspect of	orting burden of this collection of informa athering and maintaining the data neede o respond to a collection of information u this collection of information, including su RA (0920-0666).	d, and completing and reviewing the collection in the conference of the complex it displays a currently valid OMB	collection of control nu	of information. An age umber. Send comme	ency may not condu nts regarding this b	uct or spo urden esti	nsor, and a pe mate or any of	rson is not ther
CDC 57.5	00 (Front) Rev 7, V 8.6						Pag	e 1 of 9
Δ 2 Ις	plation and Screening							
				itia DO				
*11.	Does your center have capacity to isolate patients with hepatitis B? ☐ Yes, use hepatitis B isolation room ☐ Yes, use hepatitis B isolation area ☐ No hepatitis B isolation							
	☐ Yes, use hepatitis B isola	•			-			
*12.	Are patients routinely isolated or cohorted for treatment <u>within your center</u> for any of the following conditions? (if yes, select all that apply)							
	☐ No, none	☐ Hepatitis C		☐ Active tube	rculosis (TB o	disease	e)	
	☐ Vancomycin-resistan	t Enterococcus (VRE)						
	☐ Methicillin-resistant S	Staphylococcus aureus (MI	RSA)	☐ Other, spec	cify:			
*13.	☐ Before the patie room)	ed wounds with drainage, it is assessment most often intended in the treatment are the seated in the treatment.	ecal ind occur? a (e.g.	continence or d ? (select one) , at check-in or	iarrhea?		□ Yes	□ No
*14.	Does your center routinely admission to your center?	screen patients for latent to	ubercul	osis infection (L	-TBI) on		☐ Yes	□No
A.3. Pa	tient Records and Surveillar	ce						
*15.	Does your center maintain hemodialysis treatment for		re each	n patient receive	ed their		□ Yes	□ No
*16.	Does your center maintain treatment for every treatme		ed for e	each patient's h	emodialysis		□ Yes	□No
*17.	If a patient from your center infection contributed to their		en is yo	our center able	to determine	if a blo	odstream	
	☐ Always ☐ Often		□Ra	rely	□ Never	□ N/ <i>i</i>	A – not pu	rsued



Form Approved OMB No. 0920-0666 Exp. Date: www.cdc.gov/nhsn

-7//// C	lational Healthcare					,					c.gov/nhsn
*18.	How often is your center	er able to	obtain a p	oatient's m	icrobiolog	ıy lab	records		alization?		
	☐ Always ☐ 0	Often	☐ Som	netimes	☐ Rar	ely		☐ Never	□ N/A -	- not pu	rsued
*19.	Which of the following (select all that apply)	infections	in your po	eritoneal d	lialysis pa	tients	does you	ur center rou	tinely trac	k?	
	☐ Peritonitis	□F	Peritoneal	dialysis ca	atheter site	e infe	ction	☐ Other (sp	ecify)		
*20.	routinely track? (select all that apply)										
	☐ Bloodstream infection☐ Vascular access site infection		air embol	ccess dislo lism reakage or		ection		☐ Other (sp	oecify)		
	respond to the follow s to current or most rece					from	your ce	nter for the	first week	of Feb	<u>oruary</u>
B. Pati	ent and staff census										
*21.	Was your center opera	ıtional dur	ing the fir	st week of	February	?] Yes	□No
*22.	How many MAINTENANCE, NON-TRANSIENT dialysis PATIENTS were assigned to your center during the first week of February?										
	Of these, indicate the r		no receive	ed:							
	a. In-center hemo										
	b. Home hemodia	-									
	c. Peritoneal dial	ysis:									
*23.	How many acute kidne February?	ey injury (A	AKI) patiei	nts receive	ed hemodi	ialysis	s in your	center during	the first v	veek of	
*24.	How many PATIENT C of February? <i>Include o</i>	ARE staff nly staff w	f (full time /ho had di	, part time irect conta	, or affiliat act with dia	ted wi a <i>lysi</i> s	th) worke patients	ed in your ce or equipmen	nter durinç t:	g the firs	st week
	Of these, how many w	ere in eac	h of the fo	ollowing ca	ategories?)					
	a. Nurse/nurse a						Dietitian:				
	b. Dialysis patien							ns/physician	assistant:		
	c. Dialysis biome		nician:					actitioner:			
	d. Social worker:					h.	Other:				
									Pa	age 2 of 9)
C. Vac	cines										
*25.	Of the <u>dialysis</u> patients	counted	in questio	n 22, how	many rec	eived	:				
		_	•	,	•						

C. Vac	cines	
*25.	Of the	dialysis patients counted in question 22, how many received:
	a.	At least 3 doses of hepatitis B vaccine (ever)?
	b.	The influenza (flu) vaccine for the <u>current/most recent</u> flu season?
	C.	At least one dose of pneumococcal vaccine (ever)?
*26.	Of the	in-center hemodialysis patients counted in question 22a, how many received:
	a.	At least 3 doses of hepatitis B vaccine (ever)?
	b.	The influenza (flu) vaccine for the <u>current/most recent</u> flu season?
	C.	At least one dose of pneumococcal vaccine (ever)?
*27.	Of the	patient care staff members counted in question 24, how many received:
	a.	At least 3 doses of hepatitis B vaccine (ever)?



Form	App	rove
OMB No. 0	920	-066
E	Ехр.	Date
www.cdc	.aov	/nhs

	b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?
*28.	Does your center use standing orders to allow nurses to administer any of the vaccines ☐ Yes ☐ No mentioned above to patients without a specific physician order?
*29.	Which type of pneumococcal vaccine does your center offer to patients ? (choose one) □ Polysaccharide (i.e., PPSV23) only □ Conjugate (e.g., PCV13) only □ Both polysaccharide & conjugate □ Neither offered
D. He	patitis B and C
D.1. F	epatitis B
*30.	Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a: a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February? i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center? b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:
5	(i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B surface antigen)?
D.2. ⊦	epatitis C
*32.	Does your center routinely screen hemodialysis patients for hepatitis C antibody (anti-HCV) \Box Yes \Box No on admission to your center? (<i>Note: This is NOT hepatitis B core antibody</i>)
*33.	Does your center routinely screen hemodialysis patients for hepatitis C antibody (anti-HCV)
*34.	 Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis patients counted in question 22a, a. How many were hepatitis C antibody positive in the first week of February? i. Of these patients who were hepatitis C antibody positive in the first week of February, how many were positive when first admitted to your center? b. How many patients converted from hepatitis C antibody negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis C infection)? Do not include

Page 3 of 9



Form Approved OMB No. 0920-0666 Exp. Date: www.cdc.gov/nhsn

E. Dial	E. Dialysis Policies and Practices			
E.1. Dia	alyzer R	euse		
*35.	Does y	our center reuse dialyzers for any patients?	☐ Yes	□ No
	If yes,			
	a.	Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis patients counted in 2 them participate in dialyzer reuse?	2a, how m	any of
	b.	Does your center routinely test reverse osmosis (R.O.) water from the reuse room for culture and endotoxin whenever a reuse patient has a pyrogenic reaction?	☐ Yes	□ No
	C.	Of all reused dialyzers at your center, how many undergo refrigeration prior to reprocess □ All □ Most □ Some □ Few □ No	•	
	d.	Is there a limit to the number of times a dialyzer is used? ☐ Yes (indicate number):		
		☐ No limit as long as dialyzer meets certain criteria (e.g., passes pressure leak test, e	•	
	e.	Of all reused dialyzers in your center, how many of them have sealed (non-removable) h □ All □ Most □ Some □ Few □ No	•	s?
	f.	Where are dialyzers reprocessed?		
		☐ Dialyzers are reprocessed at our center only		
		☐ Dialyzers are transported to an off-site facility for reprocessing only		
		☐ Both at our center and off-site		
		If any dialyzers are reprocessed at the facility,		
		i. How is dialyzer header cleaning performed? (select all that apply)		
		☐ Automated machine (e.g., RenaClear® System)		
		☐ Spray device (e.g., ASSIST® header cleaner)		
		☐ Insertion of twist-tie or other instrument to break up clots		
		☐ Disassemble dialyzer to manually clean		
		☐ Other, specify:		
		☐ No separate header cleaning step performed		
		ii. How are dialyzers reprocessed?		
		☐ Automated reprocessing equipment		
		☐ Manual reprocessing		
E.2. Wa	ater/Dial			
*36.	What ty	pe of dialysate is used for in-center hemodialysis patients at your center? (choose one)		
		Conventional		
	ا□	Jltrapure		
*37.	Does y	our center routinely test the following whenever a patient has a pyrogenic reaction?		
	a.	Patient blood culture	□ Yes	□ No
	b.	Dialysate from the patient's dialysis machine	□ Yes	□ No
E.3. Pri	iming Pr			
*38.	Does y	our center use hemodialysis machine Waste Handling Option (WHO) ports?	□ Yes	□ No
*39.		patients in your center "bled onto the machine" (i.e., where blood is allowed to reach est reach the prime waste receptacle or WHO port)?	☐ Yes	□ No



Form Approved OMB No. 0920-0666 Exp. Date: www.cdc.gov/nhsn

E.4. Inj	ection Practices					
*40.	What form of erythropoiesis	stimulating agent (ESA) is r	most often used in your center?			
	☐ Single-dose vial	☐ Multi-dose vial	☐ Pre-packaged syringe	□ N/A		
	a. Is ESA from one sir	ngle-dose vial or syringe adn	ninistered to more than one patie	nt?] Yes	□ No
*41.	Where are medications mos	st commonly drawn into syrir	nges to prepare for patient admir	nistration? (d	choose	one)
	☐ At the individual dia	alysis stations				
	☐ On a mobile medica	ation cart within the treatmer	nt area			
	☐ At a fixed location v	vithin the patient treatment a	rea (e.g., at nurses' station)			
	☐ At a fixed location r	emoved from the patient trea	atment area (not a room)			
	☐ In a separate medic	cation room				
	☐ In a pharmacy					
	□ Other, specify:					
*42.	Do technicians administer a	any IV medications or infusat	tes (e.g., heparin, saline) in your	center?] Yes	□ No
*43.	What form of saline flush is	s most commonly used?				
	☐ Manufacturer pre-fi					
		from single-use saline vials				
		from multi-dose saline vials				
			d saline bag used for dialysis			
		from the patient's dialysis cir				
		from a common saline bag u	used for all patients			
	☐ Other (specify):					
E.5. Ar	tibiotic Use					
*44.	Does your center use the fo	ollowing means to restrict or	ensure appropriate antibiotic use	?		
	a. Have a written polic	cy on antibiotic use			∃ Yes	□ No
	b. Formulary restrictio				∃ Yes	□ No
	c. Antibiotic use appro	<u> </u>			∃ Yes	□ No
	d. Automatic stop orde	ers for antibiotics] Yes	□ No
*45.	In your center, how often ar are drawn (or without performance)		r a suspected bloodstream infect	tion <u>before</u>	blood c	ultures
		Often	es 🔲 Rarely] Neve	r
		<u> </u>				
E.6. P	revention Activities					
*46.		d in any national or regional	infection prevention-related initia	tives in \Box] Yes	□ No
	the past year?		00 (% 10 initiative and all the state			
	a. If yes, what is the <u>primary focus</u> of the initiative(s)? (if >1 initiative, select all that apply)					
	☐ Catheter reduct	1011				
	☐ Hand hygiene☐ Bloodstream inf	action prevention				
		on/engagement for infection	nrevention			
	☐ Increase vaccin		Provention			
		ove use of antibiotics				
	<u> </u>	I infection control practices				
	☐ Improve genera	<u>'</u>				



Form Approved OMB No. 0920-0666 Exp. Date: www.cdc.gov/nhsn

Other,	

Page 5 of 9

E.6. Pr	evention Activities (continued)		
	b. If yes, is your center actively participating in any of the following prevention initiatives (sele	ect all that	apply):
	☐ CDC Making Dialysis Safer for Patients Coalition – facility-level participation		
	☐ CDC Making Dialysis Safer for Patients Coalition – corporate- or other organization-le	evel nartic	ination
	☐ The Standardizing Care to improve Outcomes in Pediatric Endstage Renal Disease	•	ιραιιστί
	Collaborative Peritoneal Dialysis Catheter-related Infection Project	(0001 L)	
	☐ SCOPE Collaborative Hemodialysis Access-related Infection Project		
	☐ None of the above		
*47.	In the past year, has your center's medical director participated in a leadership or educational activity as part of the American Society of Nephrology's (ASN) Nephrologists Transforming Dialysis Safety (NTDS) Initiative?	□ Yes	□ No
*48.	Does your center follow <u>CDC-recommended Core Interventions</u> to prevent bloodstream infection hemodialysis patients?	s in	
	\square Yes, all \square Yes, some \square No, none		
*49.	Does your center perform hand hygiene audits of staff monthly (or more frequently)?	□ Yes	□ No
*50.	Does your center perform observations of staff vascular access care and catheter accessing practices quarterly (or more frequently)?	□ Yes	□ No
*51.	Does your center perform staff competency assessments for vascular access care and catheter accessing annually (or more frequently)?	□ Yes	□ No
E.7. Pe	ritoneal Dialysis		
*52.	For peritoneal dialysis catheters , is antimicrobial ointment routinely applied to the exit site during dressing change?	□ Yes	□ No
	a. If yes, what type of ointment is most commonly used? (select one)		
	☐ Gentamicin		
	☐ Mupirocin		
	☐ Povidone-iodine		
	☐ Bacitracin/polymyxin B (e.g., Polysporin®)		
	☐ Bacitracin/neomycin/polymyxin B (triple antibiotic)		
	☐ Bacitracin/gramicidin/polymyxin B (Polysporin® Triple)		
	☐ Other, specify:		
F. Vas	cular Access		
F.1. Ge	neral Vascular Access Information		
*53.	Of the MAINTENANCE, NON-TRANSIENT hemodialysis patients from question 22 (22a + 22b),		/
	received hemodialysis through each of the following access types during the first week of February	ıry?	
	a. AV fistula:		
	b. AV graft: c. Tunneled central line:		
	d. Nontunneled central line:		
	e. Other vascular access device (e.g., catheter-graft hybrid):		
E 2 A ==	<u> </u>		
*5/	eriovenous (AV) Fistulas or Grafts Refore prepring the fistula or graft site for rope-ladder cannulation, what is the site most often cla	nancod wi	th2



Form Approved
OMB No. 0920-0666
Exp. Date:
www.cdc.gov/nhsn
y: ____ □ Nothing

☐ Alcohol-based hand rub ☐ Antiseptic wipes

☐ Other, specify: _

Page 6 of 9

	eriovenous (AV) Fistulas or Grafts (continued)
*55.	Before rope-ladder cannulation of a fistula or graft, what is the site most often <u>prepped</u> with? (select one)
	☐ Alcohol
	☐ Chlorhexidine without alcohol
	☐ Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®)
	☐ Povidone-iodine (or tincture of iodine)
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol
	☐ Other, specify:
	☐ Nothing
	a. What form of this skin antiseptic is used to prep fistula/graft sites?
	☐ Multiuse bottle (e.g., poured onto gauze)
	☐ Pre-packaged swabstick/spongestick
	☐ Pre-packaged pad
	☐ Other, specify:
	□ N/A
*56.	How many of the fistula patients in your center undergo buttonhole cannulation?
50.	□ All □ Most □ Some □ None
	If any,
	a. Which fistula patients undergo buttonhole cannulation?
	☐ In-center hemodialysis patients only
	☐ Home hemodialysis patients only
	☐ Both
	If any in-center hemodialysis patients undergo buttonhole cannulation,
	b. When buttonhole cannulation is performed for in-center hemodialysis patients:
	i. Who most often performs it?
	□ Nurse
	☐ Patient (self-cannulation)
	☐ Technician
	Other, specify:
	 Before cannulation, what is the buttonhole site most often prepped with? (select the one most commonly used)
	☐ Alcohol
	☐ Chlorhexidine without alcohol
	□ Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®)
	☐ Povidone-iodine (or tincture of iodine)
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol
	☐ Other, specify:
	□ Nothing



Form Approved
OMB No. 0920-0666
Exp. Date:
www.cdc.gov/nhsn
Yes No

iii. Is antimicrobial ointment (e.g., mupirocin) routinely used at buttonhole cannulation sites to **prevent** infection?

Page 7 of 9

	F.3. H	3. Hemodialysis Catheters				
	*57.	Before accessing the hemodialysis catheter, what are the catheter hubs most commonly prepped with?				
		•	(select one)			
a.			□ Alcohol			
b.			Chlorhexidine without alcohol			
c.			Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®)			
d.			□ Povidone-iodine (or tincture of iodine)			
e.			☐ Sodium hypochlorite solution (e.g., Alcavis) without alcohol			
			☐ Sodium hypochlorite solution (e.g., Alcavis) followed by alcohol			
g.			Other, specify:			
h.			l Nothing			
		a.	What form of this antiseptic/disinfectant is used to prep the catheter	hubs?		
			☐ Multiuse bottle (e.g., poured onto gauze)			
k.			☐ Pre-packaged swabstick/spongestick			
		☐ Pre-packaged pad				
m.		☐ Other, specify:				
n.			□ N/A			
0.	*58.	Are catheter hubs routinely scrubbed after the cap is removed and before accessing the \Box Yes \Box No catheter (or before accessing the catheter via a needleless connector device, if one is used)?				
q.	*59.	commo	When the catheter dressing is changed, what is the exit site (i.e., place where the catheter enters the skin) most commonly prepped with? (select one) Alcohol			
s.		☐ Chlorhexidine without alcohol				
		☐ Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®)				
u.			Povidone-iodine (or tincture of iodine)			
v.			Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcoho	ol		
w.			Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alc	cohol		
х.			Other, specify:			
у.			Nothing			
		a.	What form of this antiseptic/disinfectant is used at the exit site?			
			☐ Multiuse bottle (e.g., poured onto gauze)			
			☐ Pre-packaged swabstick/spongestick			
		☐ Pre-packaged pad				
			☐ Other, specify:			
			□ N/A			
	*60.					
		u.	☐ Bacitracin/gramicidin/polymyxin B (Polysporin® Triple)	☐ Gentamicin		
			☐ Bacitracin/polymyxin B (e.g., Polysporin®)	☐ Mupirocin		
			☐ Bacitracin/polymyxin B (triple antibiotic)	☐ Povidone-iodine		



Form Approved
OMB No. 0920-0666
Exp. Date:

	National Healthcare Safety Network	FIC	actices Survey	www.cdc.gov/nhsn
William III.	Safety Network	Other, specify:		
*61.		job classification of staff memb perform exit site care) in your	ers who <u>most often</u> perform hemodialysis catheter care center? (select one)	(i.e., access
	☐ Nurs	e □ Technician	☐ Other, specify:	

Page 8 of 9

F.3. Hemodialysis Catheters (continued)							
"02.	Are antimicrobial lock solutions used to prevent hemodialysis catheter infections in your center?						
	☐ Yes, for all catheter patien	·					
	•	n is most commonly used? (select one)					
	☐ Sodium citrate	☐ Taurolidine					
	☐ Gentamicin	☐ Ethanol					
	□ Vancomycin □ Multi-component lock solution or other, specify:						
*63.	catheters in your center?	devices (e.g., Tego®, Q-Syte™) used on hemodialysis	☐ Yes	□ No			
	 a. If yes, for which patients 						
	□In-center hemodialysis patients only						
	☐Home hemodialysis patients only						
	□ Both						
*64.	Are any of the following routinely	used for hemodialysis catheters in your center? (select all that	at apply)				
	Chlorhexidine dressing (e.g., Biopatch®, Tegaderm™ CHG)	☐ Yes	□ No			
	Other antimicrobial dres	sing (e.g., silver-impregnated)	☐ Yes	□ No			
	Antiseptic-impregnated c	atheter cap/port protector:	!				
	3M™ Curos™ Disinfe	ecting Port Protectors	☐ Yes	□ No			
	ClearGuard® HD end	l caps	☐ Yes	□ No			
	Antimicrobial-impregnate	ed hemodialysis catheters	☐ Yes	□ No			
*65.	a. Does your center provide catheter patients with supplies to allow for changing catheter dressings outside the dialysis center?						
	☐ Yes, routinely	\square Yes, only in certain circumstances \square No					
	b. Does your center educate patients with catheters on how to shower with the catheter? (select the best response) Yes, routinely for all or most patients with a catheter Yes, only for select patients with a catheter No, patients with catheters are instructed against showering No, education and instructions are not provided on this topic Other (specify)						
	c. Does your center provide catheter patients with a protective catheter cover (e.g. Shower Shield®, Cath Dry™) to allow them to shower?						
	☐ Yes, routinely	\square Yes, only in certain circumstances \square No					



Form Approved OMB No. 0920-0666 Exp. Date: www.cdc.gov/nhsn

Comments:		
Disclaimer: Use of trade names and commercial sources is for identification only and does not imply endorsement.		

Page 9 of 9